Professional Documents
Culture Documents
A.
PATIENT IDENTITY
Name
: Mrs. S
Age
: 44 years old
Sex
: Female
Address
: Bakung lor
Religion
: Moslem
Marital Status
: Married
B.
ANAMNESIS
Main Grievance
Having enlargement of mammae
Historical of Present Disease
The patient came to the hospital of Arjawinangun because there
was a unilateral enlargement of her mammae since 2 months ago. The
patient complained of increasingly enlarged mammae. In addition to
these symptoms, patient has no other complaints.
Historical of Past Disease
Hipertension (-)
Diabetes Melitus (-)
Historical of Family Disease
Hipertension (-)
Diabetes Melitus (-)
The patient said there was no other family member that have
same disease like her
C.
MEDICAL EXAMINATION
Present Status
General Condition: Moderate
Awareness
: Composmantis
Blood Pressure : 150/100 mmHg
Pulse
: 72x/minute
Breathing
: 20x/minute
Temperature
: 37,4 C
General Status
Head
Form
: Normal, Simetrical
Hair
: Black colour, No hair fall
Eye
Anemic Conjungtival, -/-
Neck
Enlargement of lymph nodes (-)
Trachea in the middle
No mass
Thorax
Lungs pulmonary
Inspection
: The right and left of his chest shape is
symmetrical
Palpation
Abdomen
Inspection : Flat abdomen shape, supple, not visible skin disorders
Palpation
: Tenderness (-), rebound tenderness (-)
Percussion : There was a whole field tympanic abdomen
Auscultation
: Bowel (+) Normal
Ekstremity
Superior : Warm akral, edema -/-, CTR <2
Inferior : Warm akral, edema -/-, CTR <2
Genitalia : Normal
D.
INVESTIGATIONS
Laboratory Examination
Complete Blood
Leukocytes
Red Blood Cell
Hb
HCT
Platelets
BT
CT
: 6,56 10e3/uL
: 4,46 10e6/uL
: 10,1 g/dL
: 32,5 %
: 363.000 10e3/uL
: 2
: 4
E.
DIAGNOSIS OF WORK
Invasive Ductal Carcinoma Mammae Dextra
F.
DIFFERENTIAL DIAGNOSIS
G.
MANAGEMENT PLAN
Non-medical:
Radical masectomy
Medical:
Cefazolin 2x1
Ketorolac 2x1
Ranitidine 2x1
Amlodipine 1x1
H.
PROGNOSIS
Quo ad vitam
Quo ad functionam
Quo ad sanationam
: Ad Bonam
: Ad Bonam
: Ad Bonam
LITERATURE REVIEW
Background
Worldwide, breast cancer is the most frequently diagnosed life-threatening
cancer in women and the leading cause of cancer death among women. Breast
cancer is malignancy derived from the parenchyma, stroma, mammary areola and
papilla. Breast cancer is malignancy that starts from cells in the breast
subsequently grow in the breast tissue. Cancer can begin to grow in the milk
glands, milk ducts, fatty tissue and connective tissue on breast. It is particularly
common in women, but also can occurs in men.
Anatomy
Women and men both have breasts, but women have more breast tissue
than men. Each breast lies over a muscle of the chest called the pectoral muscle.
The female breast covers a fairly large area. It extends from just below the
collarbone (clavicle), to the armpit (axilla) and across to the breastbone
(sternum).
Adipose Tissue
The female breast is mostly made up of a collection of fat cells called adipose
tissue. This tissue extends from the collarbone down to the underarm and across
to the middle of the ribcage.
Lobes, Lobules, And Milk Ducts
A healthy female breast is made up of 1220 sections called lobes. Each of
these lobes is made up of many smaller lobules, the gland that produces milk in
nursing women. Both the lobes and lobules are connected by milk ducts, which
act as stems or tubes to carry the milk to the nipple. These breast structures are
generally where the cancer begins to form.
Epidemiology
The final decades of the 20th century saw worldwide increases in the
incidence of breast cancer, with the highest rates reported in Westernized
countries. Reasons for this trend are largely attributed to introduction of screening
mammography. Changes in reproductive patternsparticularly fewer children
and later age at first birthmay also have played a role, as may changes in
lifestyle factors, including the following:
The beginning of the 21st century saw a dramatic decrease in breast cancer
incidence in a number of Westernized countries (eg, the United Kingdom, France,
and Australia). These decreases paralleled those noted in the United States and
reflected similar patterns of mammography screening and decreased use of
combination HRT.
In 2008, there were an estimated 1.38 million new cases of invasive breast cancer
worldwide. The 2008 incidence of female breast cancer ranged from 19.3 cases
per 100,000 in Eastern Africa to 89.9 cases per 100,000 in Western Europe.
With early detection and significant advances in treatment, death rates from
breast cancer have been decreasing over the past 25 years in North America and
parts of Europe. In many African and Asian countries (eg, Uganda, South Korea,
Hispanic/Latina: 91.0/100,000
According to the ACS, death rates from breast cancer among women from
Hispanic/Latina: 15.3/100,000
the US have been declining since the early 1990s, except in American Indian and
Alaska Native populations, among whom rates have remained stable.
Etiology
Age and gender
Increasing age and female sex are established risk factors for breast cancer.
Sporadic breast cancer is relatively uncommon among women younger than 40
years but increases significantly thereafter. The effect of age on risk is illustrated
in the SEER (Surveillance, Epidemiology and End Results) data, where the
incidence of invasive breast cancer for women younger than 50 years is 44.0 per
100,000 as compared with 345 per 100,000 for women aged 50 years or older.
The total and age-specific incidence for breast cancer is bimodal, with the
first peak occurring at about 50 years and the second occurring at about 70 years.
This bimodal pattern may reflect the influence of age within the different tumor
subtypes; poorly differentiated, high-grade disease tend to occur earlier, whereas
hormone-sensitive, slower-growing tumors tend to occur with advancing age.
Family history of breast cancer
One or more relatives with two cancers (breast and ovarian cancer or 2
independent breast cancers)
cancers, have cancer syndromes. These include families with a mutation in the
PTEN, TP53, MLH1, MLH2, CDH1, or STK11 gene.
BRCAPRO
Couch
Myriad I and II
Manchester
All of these assessment tools are highly predictive of carrier status and aid
breast cancer. Prolonged exposure to elevated levels of sex hormones has long
been postulated as a risk factor for developing breast cancer, explaining the
association between breast cancer and reproductive behaviors.
Clinical trials of secondary prevention in women with breast cancer have
demonstrated the protective effect of selective estrogen receptor modulators
(SERMs) and aromatase inhibitors on recurrence and the development of
contralateral breast cancers. Use of SERMs in women at increased risk for breast
cancer has prevented invasive ER-positive cancers. These data support estradiol
and its receptor as a primary target for risk reduction but do not establish that
circulating hormone levels predict increase risk.
A number of epidemiologic and pooled studies support an elevated risk of
breast cancer among women with high estradiol levels. One of the most widely
studied factors in breast cancer etiology is the use of exogenous hormones in the
form of oral contraceptives (OCs) and hormone replacement therapy (HRT).
Data obtained from case-control and prospective cohort settings support an
increased risk of breast cancer incidence and mortality with the use of
postmenopausal HRT. Increased risk of breast cancer has been positively
associated with length of exposure, with the greatest risk being observed for
hormonally responsive lobular, mixed ductal-lobular, and tubular cancers. Risk is
greater among women taking combination HRT than among those taking
estrogen-only formulations. Estrogen alone was associated with increased risk
(though the increase was consistently less than that associated with combined
HRT use).
Prior breast health history
Western dietary pattern (high energy content in the form of animal fats and
refined carbohydrates)
Sedentary lifestyle
Chronic hyperinsulinemia
Alcohol consumption
the chest area, particularly during puberty, have been unequivocally linked with
an increased risk of breast cancer in adulthood. Because of the strong association
between ionizing radiation exposure and breast cancer risk, medical diagnostic
procedures are performed in such a way as to minimize exposure to the chest
area, particularly during adolescence.
Women with a history of radiation exposure to the chest area should be
examined and counseled regarding their risk of breast cancer on the basis of the
timing and dose of the previous exposure. A patient treated for Hodgkin
lymphoma with Mantel radiation that includes the breasts in the radiation field
has a 5-fold higher risk of developing breast cancer. This risk increases markedly
for women treated during adolescence[; evidence suggests that cumulative risk
increases with age as a function of age of exposure and type of therapy.
Current evidence does not support a significant and reproducible link
between other environmental exposures and breast cancer risk. Thus, a number of
factors remain suspect but unproven.
Early breast cancers may be asymptomatic, and pain and discomfort are
typically not present. If a lump is discovered, the following may indicate the
possible presence of breast cancer:
Axillary lump
To detect subtle changes in breast contour and skin tethering, the examination
must include an assessment of the breasts with the patient upright with arms
raised. The following findings should raise concern:
Skin tethering
Nipple inversion
Dilated veins
Ulceration
Hardness
Irregularity
Focal nodularity
Breathing difficulties
Bone pain
Symptoms of hypercalcemia
Abdominal distention
Jaundice
Headache
The clinical evaluation should include a thorough assessment of specific risk
factors for breast cancer such as age related, lifestyle, use of estrogenprogesterone hormone replacement therapy (HRT), current or recent oral
contraceptive use, and reproductive history.
Pathophysiology
The current understanding of breast cancer etiopathogenesis is that invasive
cancers arise through a series of molecular alterations at the cell level. These
alterations result in breast epithelial cells with immortal features and uncontrolled
growth.
Luminal A
Luminal B
Basal-like
HER2-positive
Over the past 25 years, the incidence of lobular carcinoma in situ (LCIS) has
doubled, reaching a current level of 2.8 per 100,000 women; the peak
incidence is in women aged 40-50 years
Infiltrating lobular carcinoma accounts for fewer than 15% of invasive breast
cancers
Tubular carcinoma of the breast accounts for 1-2% of all breast cancers
Metaplastic breast cancer accounts for fewer than 1% of breast cancer cases,
tends to occur in older women (average age of onset in the sixth decade), and
has a higher incidence in blacks
Mammary Paget disease accounts for 1-4% of all breast cancers and has a peak
incidence in the sixth decade of life (mean age, 57 years).
Diagnosis
Breast cancer is often first detected as an abnormality on a mammogram
before it is felt by the patient or health care provider.
Evaluation of breast cancer includes the following:
Clinical examination
Imaging
Needle biopsy
Physical examination
The following physical findings should raise concern:
Skin tethering
Nipple inversion
Dilated veins
Ulceration
Paget disease
If a palpable lump is found and possesses any of the following features, breast
cancer may be present:
Hardness
Irregularity
Focal nodularity
Screening
Early detection remains the primary defense in preventing breast cancer. Screening
modalities include the following:
Breast self-examination
Mammography
Ultrasonography
Ultrasonography and MRI are more sensitive than mammography for invasive
cancer in nonfatty breasts. Combined mammography, clinical examination, and
MRI are more sensitive than any other individual test or combination of tests.
Biopsy
Core biopsy with image guidance is the recommended diagnostic approach for
newly diagnosed breast cancers. This is a method for obtaining breast tissue
without surgery and can eliminate the need for additional surgeries. Open
excisional biopsy is the surgical removal of the entire lump.
Management
Surgery is considered primary treatment for early-stage breast cancer; many
patients are cured with surgery alone. The goals of breast cancer surgery include
complete resection of the primary tumor with negative margins to reduce the risk
of local recurrences and pathologic staging of the tumor and axillary lymph nodes
(ALNs) to provide necessary prognostic information.
Adjuvant treatment of breast cancer is designed to treat micrometastatic
disease (ie, breast cancer cells that have escaped the breast and regional lymph
nodes but which have not yet had an established identifiable metastasis).
Adjuvant treatment for breast cancer involves radiation therapy and systemic
therapy (including a variety of chemotherapeutic, hormonal and biologic agents).
Surgery and radiation therapy, along with adjuvant hormone or
chemotherapy when indicated, are now considered primary treatment for breast
cancer. Surgical therapy may consist of lumpectomy or total mastectomy.
Radiation therapy may follow surgery in an effort to eradicate residual disease
while reducing recurrence rates. There are 2 general approaches for delivering
radiation therapy:
Docetaxel
Cyclophosphamide
Doxorubicin
Carboplatin
Methotrexate
Trastuzumab
Two selective estrogen receptor modulators (SERMs), tamoxifen and
raloxifene, are approved for reduction of breast cancer risk in high-risk women.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer
who are at high risk for fracture, the monoclonal antibody denosumab or either of
the bisphosphonates zoledronic acid and pamidronate may be added to the
treatment regimen to increase bone mass. These agents are given along with
Prognosis
Overall, patients with mucinous carcinoma have an excellent prognosis,
with better than 80% 10-year survival. Similarly, tubular carcinoma has a low
incidence of lymph node involvement and a very high overall survival rate.
Because of the favorable prognosis, these patients are often treated with only
breast-conserving surgery and local radiation therapy.
REFFERENCE
1. Chalasani,
Pavani.
Breast
Cancer.
(2015).
[Online].
Available:
al. Environmental tobacco smoke and breast cancer incidence. Environ Res.
2004 Oct. 96(2):176-85. [Medline].
3. Jatoi I, Anderson WF, Rosenberg PS. Qualitative age-interactions in breast
cancer: a tale of two diseases? doi: 10.1097/COC.0b013e3181844d1c. Am J
Clin Oncol. 2008 Oct. 31(5):504-6. [Medline].
4. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu
Rev Public Health. 1996. 17:47-67. [Medline].
5. Breast
Anatomy.
http://www.nationalbreastcancer.org/breast-anatomy.
Diakses pada 19 May 2016 Pukul 20.00.
6. Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, AntonCulver H, et al. Validity of models for predicting BRCA1 and BRCA2
mutations. Ann Intern Med. 2007 Oct 2. 147(7):441-50. [Medline]. [Full
Text].
7. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al.
BRCA1 and BRCA2 mutations account for a large proportion of ovarian
carcinoma cases. Cancer. 2005 Dec 15. 104(12):2807-16. [Medline].
8. [Guideline] Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine
RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the
American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 1.
19(5):1539-69. [Medline].
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin.
2015 Jan-Feb. 65(1):5-29. [Medline].
10. Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets:
Breast.
Available
at
http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality.
Accessed: May 17 , 2016.
11. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global
cancer statistics, 2012. CA Cancer J Clin. 2015 Mar. 65(2):87-108. [Medline].
12. The Cancer Genome Atlas Network. Comprehensive molecular portraits of
human breast tumours. Nature. 2012 Oct 4. 490(7418):61-70. [Medline]. [Full
Text].
13. Yudhautama,
Herry
dr.
Breast
Cancer
At
Aglance.
http://herryyudha.blogspot.co.id/2012/11/brt-aglanceeast-cancer-a.html?
spref=bl . Diakses pada 19 Mei 2016 pukul 21.00.